Glioblastoma Multiforme (GBM) Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment (Surgery, Radiation therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy), By Drug Class (Temozolomide, Bevaci
Description
The global glioblastoma multiforme (GBM) treatment market size is expected to reach USD 7.02 billion by 2034 according to a new study by Polaris Market Research. The report “Glioblastoma Multiforme (GBM) Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment (Surgery, Radiation therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, and Immunotherapy), By Drug Class (Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, and Others), By End-Use, By Region; Segment Forecast, 2025 - 2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The growing cases of brain tumors globally, along with glioblastoma multiforme, are the chief impelling factor that drives the market growth. Besides, the rising number of R&D activities for effective surgical alternatives, the growing geriatric population, the introduction of updated techniques for diagnosis, and rapid advancements in drug delivery technologies may further act as a catalyzing factor for global industry demand in the foreseeable period. The rate of conventional therapies is high, creating an increasing need for innovative solutions. This increased need has boosted investment in areas such as personalized medicine and tumor-treating fields. This rise in demand, with regulatory support for breakthrough therapies, accelerated the development of new GBM treatments. Thus, the market is expected to witness expansion with advances in R&D efforts aimed at enhancing clinical availability.
The demand for novel and competent drugs is increasing as they are more likely to present effective surgery. According to an April 2024, American Association of Neurological Surgeons report Glioblastoma has an incidence of 3.21 per 100,000 population. Accordingly, this is an alarming growth rate because the fatality of the patients is exponentially grown owing to the unavailability of the appropriate surgery. This growth requires effective therapies and drugs that help in decreasing the number of fatalities and may increase the life expectancy rate of the patients. Therefore, these are the certain factors that may create a lucrative opportunity for market growth around the world. There are various industry vendors introducing their innovations across the global industry to reinforce their geographical footprints. For instance, in April 2021, Humanigen Inc.- a clinical-stage biopharmaceutical company, declared the positive results from its Phase 1 clinical trial of “Ifabotuzumab” in the surgery of glioblastoma multiforme. The company announces the positive results of its Humaneered antibody, Ifabotuzumab. The drug was confirmed to be very responsive, precise, and reproducible targeting the tumor and tumor microenvironment in all patients.
Market participants such as Merck & Co., Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Amgen, Inc., Arbor Pharmaceuticals, LLC, Amgen, Inc., Teva Pharmaceutical Industries Ltd., Karyopharm Therapeutics, Inc., and Pfizer Inc. are some of the key players operating in the global industry.
Polaris Market research has segmented the glioblastoma multiforme (GBM) treatment market report on the basis of treatment, drug class, end-use, and region:
Glioblastoma Multiforme (GBM) Treatment, Treatment Outlook (Revenue - USD Billion, 2020 - 2034)
Surgery
Radiation therapy
Chemotherapy
Targeted Therapy
Tumor Treating Field (TTF) Therapy
Immunotherapy
Glioblastoma Multiforme (GBM) Treatment, Drug Class Outlook (Revenue - USD Billion, 2020 - 2034)
Temozolomide
Bevacizumab
Lomustine
Carmustine Wafers
Others
Glioblastoma Multiforme (GBM) Treatment, End-use Outlook (Revenue - USD Billion, 2020 - 2034)
Hospitals
Clinics
Ambulatory Surgical Centers
Glioblastoma Multiforme (GBM) Treatment, Regional Outlook (Revenue - USD Billion, 2020 - 2034)
North America
U.S
Canada
Europe
France
Germany
UK
Italy
Spain
Netherlands
Austria
Asia Pacific
China
India
Japan
Malaysia
South Korea
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
The growing cases of brain tumors globally, along with glioblastoma multiforme, are the chief impelling factor that drives the market growth. Besides, the rising number of R&D activities for effective surgical alternatives, the growing geriatric population, the introduction of updated techniques for diagnosis, and rapid advancements in drug delivery technologies may further act as a catalyzing factor for global industry demand in the foreseeable period. The rate of conventional therapies is high, creating an increasing need for innovative solutions. This increased need has boosted investment in areas such as personalized medicine and tumor-treating fields. This rise in demand, with regulatory support for breakthrough therapies, accelerated the development of new GBM treatments. Thus, the market is expected to witness expansion with advances in R&D efforts aimed at enhancing clinical availability.
The demand for novel and competent drugs is increasing as they are more likely to present effective surgery. According to an April 2024, American Association of Neurological Surgeons report Glioblastoma has an incidence of 3.21 per 100,000 population. Accordingly, this is an alarming growth rate because the fatality of the patients is exponentially grown owing to the unavailability of the appropriate surgery. This growth requires effective therapies and drugs that help in decreasing the number of fatalities and may increase the life expectancy rate of the patients. Therefore, these are the certain factors that may create a lucrative opportunity for market growth around the world. There are various industry vendors introducing their innovations across the global industry to reinforce their geographical footprints. For instance, in April 2021, Humanigen Inc.- a clinical-stage biopharmaceutical company, declared the positive results from its Phase 1 clinical trial of “Ifabotuzumab” in the surgery of glioblastoma multiforme. The company announces the positive results of its Humaneered antibody, Ifabotuzumab. The drug was confirmed to be very responsive, precise, and reproducible targeting the tumor and tumor microenvironment in all patients.
Market participants such as Merck & Co., Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Amgen, Inc., Arbor Pharmaceuticals, LLC, Amgen, Inc., Teva Pharmaceutical Industries Ltd., Karyopharm Therapeutics, Inc., and Pfizer Inc. are some of the key players operating in the global industry.
Polaris Market research has segmented the glioblastoma multiforme (GBM) treatment market report on the basis of treatment, drug class, end-use, and region:
Glioblastoma Multiforme (GBM) Treatment, Treatment Outlook (Revenue - USD Billion, 2020 - 2034)
Surgery
Radiation therapy
Chemotherapy
Targeted Therapy
Tumor Treating Field (TTF) Therapy
Immunotherapy
Glioblastoma Multiforme (GBM) Treatment, Drug Class Outlook (Revenue - USD Billion, 2020 - 2034)
Temozolomide
Bevacizumab
Lomustine
Carmustine Wafers
Others
Glioblastoma Multiforme (GBM) Treatment, End-use Outlook (Revenue - USD Billion, 2020 - 2034)
Hospitals
Clinics
Ambulatory Surgical Centers
Glioblastoma Multiforme (GBM) Treatment, Regional Outlook (Revenue - USD Billion, 2020 - 2034)
North America
U.S
Canada
Europe
France
Germany
UK
Italy
Spain
Netherlands
Austria
Asia Pacific
China
India
Japan
Malaysia
South Korea
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Table of Contents
110 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. U.S. Roofing Anchors Market Insights
- 4.1. Roofing Anchors Market – Market Snapshot
- 4.2. Roofing Anchors Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Commercial Construction Expansion
- 4.2.1.2. Stringent Worker Safety Regulations
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Initial Investment
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Roofing Anchors Market End Use Trends
- 4.6. Value Chain Analysis
- 5. U.S. Roofing Anchors Market, by Roof Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. U.S. Roofing Anchors Market, by Roof Type, 2020-2034 (USD Million)
- 5.3. Flat Roof
- 5.3.1. U.S. Roofing Anchors Market, by Flat Roof 2020-2034 (USD Million)
- 5.4. Pitched Roof
- 5.4.1. U.S. Roofing Anchors Market, by Pitched Roof, 2020-2034 (USD Million)
- 6. U.S. Roofing Anchors Market, by End Use
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. U.S. Roofing Anchors Market, by End Use, 2020-2034 (USD Million)
- 6.3. Residential
- 6.3.1. U.S. Roofing Anchors Market, by Residential, 2020-2034 (USD Million)
- 6.4. Commercial
- 6.4.1. U.S. Roofing Anchors Market, by Commercial, 2020-2034 (USD Million)
- 6.5. Industrial
- 6.5.1. U.S. Roofing Anchors Market, by Industrial, 2020-2034 (USD Million)
- 6.6. Institutional
- 6.6.1. U.S. Roofing Anchors Market, by Institutional, 2020-2034 (USD Million)
- 7. Competitive Landscape
- 7.1. Expansion and Acquisition Analysis
- 7.1.1. Expansion
- 7.1.2. Acquisitions
- 7.2. Partnerships/Collaborations/Agreements/Exhibitions
- 8. Company Profiles
- 8.1. 3M
- 8.1.1. Company Overview
- 8.1.2. Financial Performance
- 8.1.3. Product Benchmarking
- 8.1.4. Recent Development
- 8.2. FallTech
- 8.2.1. Company Overview
- 8.2.2. Financial Performance
- 8.2.3. Product Benchmarking
- 8.2.4. Recent Development
- 8.3. Guardian Fall Protection
- 8.3.1. Company Overview
- 8.3.2. Financial Performance
- 8.3.3. Product Benchmarking
- 8.3.4. Recent Development
- 8.4. Honeywell International Inc.
- 8.4.1. Company Overview
- 8.4.2. Financial Performance
- 8.4.3. Product Benchmarking
- 8.4.4. Recent Development
- 8.5. Kee Safety Ltd.
- 8.5.1. Company Overview
- 8.5.2. Financial Performance
- 8.5.3. Product Benchmarking
- 8.5.4. Recent Development
- 8.6. MSA Safety Incorporated
- 8.6.1. Company Overview
- 8.6.2. Financial Performance
- 8.6.3. Product Benchmarking
- 8.6.4. Recent Development
- 8.7. Petzl
- 8.7.1. Company Overview
- 8.7.2. Financial Performance
- 8.7.3. Product Benchmarking
- 8.7.4. Recent Development
- 8.8. Super Anchor Safety
- 8.8.1. Company Overview
- 8.8.2. Financial Performance
- 8.8.3. Product Benchmarking
- 8.8.4. Recent Development
- 8.9. Tractel Group
- 8.9.1. Company Overview
- 8.9.2. Financial Performance
- 8.9.3. Product Benchmarking
- 8.9.4. Recent Development
- 8.10. WernerCo
- 8.10.1. Company Overview
- 8.10.2. Financial Performance
- 8.10.3. Product Benchmarking
- 8.10.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.